Skip to main content

Table 1 Individual patients and treatment characteristics

From: Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial

Patient number 1 2 3 4 5 6 7 8 9
Menstrual status Premenopausal Postmenopausal Premenopausal Premenopausal Postmenopausal Premenopausal surgically sterilized Postmenopausal Premenopausal
ECOG performance status 1 0 1 0 0 0 0 0 0
Hormone receptor status (PR/ER) PR pos/ER pos PR pos/ER pos negative PR pos/ER pos PR pos/ER pos negative negative PR pos/ER neg PR neg/ER pos
Metastatic at initial diagnosis No No Yes No No No No No Yes
Number of metastatic sites          
  Target lesions 4 5 1 2 1 3 1 2 1
  Non-target lesions 1 3 1 2 2 2 2 2 1
Site of metastatic disease Liver Liver Lung Lung Lung Lymphnodes Lung Thoracic wall Liver
  Bone Lung Liver Lymphnodes   Bone   Skin Bone
Prior neo-adjuvant treatment Yes No No No No Yes Yes Yes No
Prior adjuvant treatment No Yes No Yes Yes Yes No No No
Prior metastatic treatment          
  Endocrine therapy first line No No No No No No No first line
  Chemotherapy second line first/second/third line first/second/third line first/second line first/second line first/second line first/second line first line first/second/third line
  Trastuzumab first line first line first line first line first line first line No first line first line
  Lapatinib second line second line second line second line second line second line first line second line third line